Michael Gelband’s Fulcrum Therapeutics FULC Stock Holding History

Michael Gelband’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,172	Closed	-$178K	–	1734
2026 Q1	$178K	Buy	+23,172	New	+$215K	﹤0.01%	1393
2024 Q3	–	Sell	-150,505	Closed	-$933K	–	1776
2024 Q2	$933K	Buy	150,505 +129,086	+603%	+$978K	0.01%	1042
2024 Q1	$202K	Sell	21,419 -30,245	-59%	-$270K	﹤0.01%	1353
2023 Q4	$349K	Buy	+51,664	New	+$229K	﹤0.01%	1135

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's FULC Position: Q2 2026 in Review

Michael Gelband sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 23,172 shares — an estimated $178K sold.

Michael Gelband first reported a position in FULC in Q4 2023 and held it in 4 quarters. The position peaked at $933K in Q2 2024. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Michael Gelband reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 23,172 Fulcrum Therapeutics shares in Q2 2026, an estimated $178K.
Michael Gelband first reported a position in Fulcrum Therapeutics in Q4 2023 and held it in 4 quarters.
Michael Gelband's Fulcrum Therapeutics position peaked at $933K in Q2 2024.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.